Nanocarriers and macrophage interaction: from a potential hurdle to an alternative therapeutic strategy

• Naths Grazia Sukubo,
• Paolo Bigini and
• Annalisa Morelli

Beilstein J. Nanotechnol. 2025, 16, 97–118, doi:10.3762/bjnano.16.10

Mechanistic insights into endosomal escape by sodium oleate-modified liposomes

• Ebrahim Sadaqa,
• Satrialdi,
• Fransiska Kurniawan and
• Diky Mudhakir

Beilstein J. Nanotechnol. 2024, 15, 1667–1685, doi:10.3762/bjnano.15.131

• leads to toxicity and diminishes their therapeutic value [4][6]. Additionally, the necessity for chemical conjugation between CPPs and therapeutic agents introduces complexities that can affect the pharmacokinetic profile and biodistribution of the drug. Alternative approaches, such as the use of

Biomimetic nanocarriers: integrating natural functions for advanced therapeutic applications

• Hugo Felix Perini,
• Beatriz Sodré Matos,
• Carlo José Freire de Oliveira and
• Marcos Vinicius da Silva

Beilstein J. Nanotechnol. 2024, 15, 1619–1626, doi:10.3762/bjnano.15.127

• such as: loss of stability, low efficiency in crossing biological barriers, inadequate efficacy in reaching target active molecules, and poor biodistribution [13][14]. Nanocarriers are employed to transport raw materials, which can be vesicles or solid nanoparticles [15]. Despite the significant

Liver-targeting iron oxide nanoparticles and their complexes with plant extracts for biocompatibility

• Shushanik A. Kazaryan,
• Seda A. Oganian,
• Gayane S. Vardanyan,
• Anatolie S. Sidorenko and
• Ashkhen A. Hovhannisyan

Beilstein J. Nanotechnol. 2024, 15, 1593–1602, doi:10.3762/bjnano.15.125

• adverse reactions. The toxicity of MNPs depends on various factors such as size, shape, structure, surface modification, concentration, dosage, biodistribution, bioavailability, solubility, immunogenicity, and pharmacokinetics [23][24]. Their use in some clinical applications is limited by low solubility

• and toxicity effects; as of May 2024, the website clinicaltrials.gov listed data on the development of 51 clinical protocols involving iron oxides NPs [25][26][27]. Surface chemistry and delivery route of MNPs affect their biodistribution patterns and circulation time in the body [28]. It is known

• that MNPs larger than 200 nm are captured by the spleen through mechanical filtration, while MNPs smaller than 10 nm can be eliminated via renal clearance. Therefore, the 10–100 nm range is considered optimal for administration in specific applications [29]. The biodistribution patterns of these

The round-robin approach applied to nanoinformatics: consensus prediction of nanomaterials zeta potential

• Dimitra-Danai Varsou,
• Arkaprava Banerjee,
• Joyita Roy,
• Kunal Roy,
• Giannis Savvas,
• Haralambos Sarimveis,
• Ewelina Wyrzykowska,
• Mateusz Balicki,
• Tomasz Puzyn,
• Georgia Melagraki,
• Iseult Lynch and
• Antreas Afantitis

Beilstein J. Nanotechnol. 2024, 15, 1536–1553, doi:10.3762/bjnano.15.121

• NMs and accelerate regulatory decision-making procedures [2][5][13]. An IATA scheme for the prediction of the short-term regional lung-deposited dose of inhaled inorganic NMs in humans following acute exposure and the longer-term NM biodistribution after inhalation, has already been presented [14

Polymer lipid hybrid nanoparticles for phytochemical delivery: challenges, progress, and future prospects

• Iqra Rahat,
• Pooja Yadav,
• Aditi Singhal,
• Mohammad Fareed,
• Jaganathan Raja Purushothaman,
• Mohammed Aslam,
• Raju Balaji,
• Sonali Patil-Shinde and
• Md. Rizwanullah

Beilstein J. Nanotechnol. 2024, 15, 1473–1497, doi:10.3762/bjnano.15.118

Nanotechnological approaches for efficient N2B delivery: from small-molecule drugs to biopharmaceuticals

• Selin Akpinar Adscheid,
• Akif E. Türeli,
• Nazende Günday-Türeli and
• Marc Schneider

Beilstein J. Nanotechnol. 2024, 15, 1400–1414, doi:10.3762/bjnano.15.113

• for CNS targeting. For example, size, shape, and surface characteristics of a DDS directly affect cellular transport and uptake, biodistribution, and the interaction with biological interfaces [64][65]. Regarding particle size, NPs with a size of approx. 15 nm or below were observed to penetrate the

Interaction of graphene oxide with tannic acid: computational modeling and toxicity mitigation in C. elegans

• Romana Petry,
• James M. de Almeida,
• Francine Côa,
• Felipe Crasto de Lima,
• Diego Stéfani T. Martinez and
• Adalberto Fazzio

Beilstein J. Nanotechnol. 2024, 15, 1297–1311, doi:10.3762/bjnano.15.105

• interaction of GO with tannic acid (TA) and its consequences for GO toxicity. We focused on understanding how TA interacts with GO, its impact on the material surface chemistry, colloidal stability, as well as, toxicity and biodistribution using the Caenorhabditis elegans model. Employing computational

• toxicity and highlight the potential of tannic acid for the synthesis and surface functionalization of graphene-based nanomaterials, offering insights into safer nanotechnology development. Keywords: biodistribution; density functional theory; ecotoxicity; molecular dynamics; surface interactions

• understand how GO’s toxicity changes regarding surface modifications such as interactions with biomolecules. In this study, we investigate the interaction of GO with TA linked to its impacts on surface chemistry, colloidal stability, lethality, and biodistribution in the C. elegans model for the first time

Dual-functionalized architecture enables stable and tumor cell-specific SiO₂NPs in complex biological fluids

• Iris Renata Sousa Ribeiro,
• Raquel Frenedoso da Silva,
• Romênia Ramos Domingues,
• Adriana Franco Paes Leme and
• Mateus Borba Cardoso

Beilstein J. Nanotechnol. 2024, 15, 1238–1252, doi:10.3762/bjnano.15.100

• to the formation of aggregates of NPs and activation of unplanned biological pathways (e.g., the complement system) [16][17][18]. The factors mentioned above hamper the biodistribution of nanomedicines and their targeting efficiency, therefore causing adverse effects. Multiple functionalization

Realizing active targeting in cancer nanomedicine with ultrasmall nanoparticles

• André F. Lima,
• Giselle Z. Justo and
• Alioscka A. Sousa

Beilstein J. Nanotechnol. 2024, 15, 1208–1226, doi:10.3762/bjnano.15.98

• value (1.8 nM) compared to the free PMSA-targeting ligand (4.5 nM). Urinary clearance in healthy mice was found to be 26% ID at 4 h p.i., reaching a total clearance of 53% ID at day 7. Biodistribution studies performed 24 h p.i. revealed that the particles accumulated to 5% ID/g or less in major organs

• microenvironment, thus enhancing treatment efficacy. The study revealed that 64Cu-Cu@CuOx-ECL1i exhibited suitable biodistribution and biocompatibility. Moreover, 64Cu-Cu@CuOx-ECL1i-Gem was able to induce tumor inhibition and to prolong survival in a syngeneic xenograft mouse model of PDAC. 5.7 Antibody-based

• ) Preparation of AuNCs through a one-pot synthesis with c(RGDyc) peptides. The targeted AuNCs were evaluated as radiotherapy sensitizers in tumor-bearing mice. (B) Biodistribution, including tumor accumulation, of targeted vs non-targeted AuNCs. (C) Photographs of dissected tumor tissues following treatment. (D

Introducing third-generation periodic table descriptors for nano-qRASTR modeling of zebrafish toxicity of metal oxide nanoparticles

• Supratik Kar and
• Siyun Yang

Beilstein J. Nanotechnol. 2024, 15, 1142–1152, doi:10.3762/bjnano.15.93

• , through aggregation, cause localized toxicity to zebrafish. Additionally, their size affects biodistribution and clearance, with larger MONPs tending to accumulate within the zebrafish organism, further exacerbating toxicity (Figure 3). In zebrafish, these mechanisms can manifest in several ways

Recent updates in applications of nanomedicine for the treatment of hepatic fibrosis

• Damai Ria Setyawati,
• Fransiska Christydira Sekaringtyas,
• Riyona Desvy Pratiwi,
• A’liyatur Rosyidah,
• Rohimmahtunnissa Azhar,
• Nunik Gustini,
• Gita Syahputra,
• Idah Rosidah,
• Etik Mardliyati,
• Tarwadi and
• Sjaikhurrizal El Muttaqien

Beilstein J. Nanotechnol. 2024, 15, 1105–1116, doi:10.3762/bjnano.15.89

• played an important role in the enhancement of therapeutic outcomes compared to those of conventional therapy. At the same time, nanoparticle drug delivery systems offer a significant reduction in side effects of treatments by lowering the off-target biodistribution of the active pharmaceutical

• uptake in a time-dependent manner. Ultimately, the nanocomplex showed excellent in vitro gene-silencing activities, that is, approximately 80–85% of the Pcbp2 mRNA expression was inhibited in activated HSCs-T6 cells after gene transfection for 24 h. The in vivo biodistribution showed that the nanocomplex

Unveiling the potential of alginate-based nanomaterials in sensing technology and smart delivery applications

• Shakhzodjon Uzokboev,
• Khojimukhammad Akhmadbekov,
• Ra’no Nuritdinova,
• Salah M. Tawfik and
• Yong-Ill Lee

Beilstein J. Nanotechnol. 2024, 15, 1077–1104, doi:10.3762/bjnano.15.88

• . These functional groups can include ligands or antibodies that specifically bind to the target cells or tissues [51]. Stimuli-responsive nanoparticles help reduce toxicity and control drug biodistribution [46]. Alginate-based nanoparticles The preparation methods of alginate-based nanoparticles The

Entry of nanoparticles into cells and tissues: status and challenges

• Kirsten Sandvig,
• Tore Geir Iversen and
• Tore Skotland

Beilstein J. Nanotechnol. 2024, 15, 1017–1029, doi:10.3762/bjnano.15.83

• cancer treatment, the goal being to increase the fraction of injected drug delivered to the tumor and thereby improve the therapeutic effect and decrease side effects. Thus, we discuss how NPs are delivered to tumors and some challenges related to investigations of biodistribution, pharmacokinetics, and

• excretion. Finally, we discuss requirements for bringing NPs into clinical use and aspects when it comes to usage of complex and slowly degraded or nondegradable NPs. Keywords: biodegradable; biodistribution; endocytosis; extracellular vesicles; nanomedicine; nanoparticles; Introduction Nanoparticles (NPs

• ) are important tools to diagnose and treat diseases, and have proven useful in basic mechanistic studies of cells and animals. Thus, knowledge about cellular uptake, intracellular transport, and metabolism of NPs in cells, as well as their biodistribution, degradation, and excretion following

Cholesterol nanoarchaeosomes for alendronate targeted delivery as an anti-endothelial dysfunction agent

• Horacio Emanuel Jerez,
• Yamila Roxana Simioni,
• Kajal Ghosal,
• Maria Jose Morilla and
• Eder Lilia Romero

Beilstein J. Nanotechnol. 2024, 15, 517–534, doi:10.3762/bjnano.15.46

• properties is a pharmacological challenge that could be addressed by formulating ALN in nanomedicines. Properly designed, intravenously administered nanomedicines allow one to control pharmacokinetics, biodistribution, and pharmacodynamics of loaded active ingredients [19]. Inflamed endothelia present

Classification and application of metal-based nanoantioxidants in medicine and healthcare

• Nguyen Nhat Nam,
• Nguyen Khoi Song Tran,
• Tan Tai Nguyen,
• Nguyen Ngoc Trai,
• Nguyen Phuong Thuy,
• Hoang Dang Khoa Do,
• Nhu Hoa Thi Tran and
• Kieu The Loan Trinh

Beilstein J. Nanotechnol. 2024, 15, 396–415, doi:10.3762/bjnano.15.36

• lipoprotein receptor-related protein overexpressed on cells that comprise the BBB. Figure 3 illustrates the biodistribution and ROS scavenging activity of edaravone-encapsulated nanospherical albumin (EeNA) [91]. Alzheimer’s disease is a neurological disease that slowly destroys thinking skills and memory

Nanomedicines against Chagas disease: a critical review

• Maria Jose Morilla,
• Kajal Ghosal and
• Eder Lilia Romero

Beilstein J. Nanotechnol. 2024, 15, 333–349, doi:10.3762/bjnano.15.30

• low tissue distributions in healthy mice [56]. By loading into intravenously administered nanomedicines, the biodistribution of poorly permeable and poorly soluble drugs could be controlled, and their activity against selected targets improved. For BNZ, the avoidance of healthy tissues and the

• reduction of hepatic first-pass metabolism is expected to minimize its toxicity [57][58]. Except on immediately accessible targets such as epithelia, however, controlled biodistribution of nanomedicines requires intravenous injection [59][60]. A fraction of injected nanomedicines would passively accumulate

• liposomes aimed to reduce the toxicity of oncological drugs by changing their biodistribution and pharmacodynamics, requiring intravenous administration. The success rate from phase 1 to approval, of antitumor nanomedicines is 6%, compared with 3.4% for classical oncological drugs [96]. The newest

Elasticity, an often-overseen parameter in the development of nanoscale drug delivery systems

• Agnes-Valencia Weiss and
• Marc Schneider

Beilstein J. Nanotechnol. 2023, 14, 1149–1156, doi:10.3762/bjnano.14.95

• biological effects the cell type (i.e., epithelial, immune, or even more organ-specific cells) should be monitored and well documented. This will hopefully allow for the separation and better understanding of the obtained results, such as biodistribution, tissue accumulation, and cellular uptake. We are

Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics

• Mamta Kumari,
• Amitabha Acharya and
• Praveen Thaggikuppe Krishnamurthy

Beilstein J. Nanotechnol. 2023, 14, 912–926, doi:10.3762/bjnano.14.75

• corona-coated NPs increases the targeting capacity. These strategies are useful to shield the effect of protein corona formation and, therefore, improve the biodistribution profile and targeting efficacies of the NPs [86]. Therapeutic applications of the antibody-conjugated NPs High metastasis rates

Overview of mechanism and consequences of endothelial leakiness caused by metal and polymeric nanoparticles

• Magdalena Lasak and
• Karol Ciepluch

Beilstein J. Nanotechnol. 2023, 14, 329–338, doi:10.3762/bjnano.14.28

• therapeutic effectiveness, regulated pharmacokinetics, known biodistribution, and minimal side effects are being sought. The mechanism of NanoEL shows great potential for future biomedical applications, but a more thorough investigation is still required [5]. Conclusion Effective transport of NPs to the

Nanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer

• Filip Gorachinov,
• Fatima Mraiche,
• Diala Alhaj Moustafa,
• Ola Hishari,
• Yomna Ismail,
• Jensa Joseph,
• Maja Simonoska Crcarevska,
• Marija Glavas Dodov,
• Nikola Geskovski and
• Katerina Goracinova

Beilstein J. Nanotechnol. 2023, 14, 240–261, doi:10.3762/bjnano.14.23

• with hyaluronic acid–doxorubicin NPs layered by electrostatic adsorption upon the micelle surface. Hyaluronic acid was used for CD44 targeting (a receptor that is often overexpressed on the surface of lung tumor cells), as well as for the optimization of biodistribution, improved tumor homing potential

• membrane-decorated NPs, platelet membrane-coated core–shell nanovesicles, and cancer cell membrane-coated nanoparticles are also versatile biomimetic nanocarriers showing improved biodistribution and increased tumor-homing potential [127][128][129][130]. Among them, cancer cell membrane biomimetic NPs may

• , they play an important role in cancer development [139][140]. However, efficacy or functional delivery cannot be predicted by solely considering the biodistribution. Endothelial transcytosis and improved tropism to tumor tissue/cells, internalization rate, intracellular trafficking, and endosomal

Orally administered docetaxel-loaded chitosan-decorated cationic PLGA nanoparticles for intestinal tumors: formulation, comprehensive in vitro characterization, and release kinetics

• Sedat Ünal,
• Osman Doğan and
• Yeşim Aktaş

Beilstein J. Nanotechnol. 2022, 13, 1393–1407, doi:10.3762/bjnano.13.115

• . Pharmaceutically, clinical failure due to a drug’s wide biodistribution and non-selective toxicity is one of the major challenges of chemotherapy. In addition, parenteral drug administration in chronic diseases that require long-term drug use, such as intestinal tumors, is challenging in terms of patient

• approaches in the treatment of colon carcinomas as well as of many other diseases [10][11][12][13]. Cancer chemotherapy is still mostly administered parenterally, which is a negative factor in terms of patient comfort. Also, non-specific wide biodistribution of the drug after parenteral administration can

Engineered titania nanomaterials in advanced clinical applications

• Padmavati Sahare,
• Paulina Govea Alvarez,
• Juan Manual Sanchez Yanez,
• Gabriel Luna-Bárcenas,
• Samik Chakraborty,
• Sujay Paul and
• Miriam Estevez

Beilstein J. Nanotechnol. 2022, 13, 201–218, doi:10.3762/bjnano.13.15

• integrin clustering and focal adhesion development. In this context, Chen et al. employed the adsorption of functional proteins (bone morphogenetic protein 2 and sclerostin antibody) to modify TiO2 nanotube arrays to repair bone fractures [35]. The PC alters biodistribution, biological identity and

Biocompatibility and cytotoxicity in vitro of surface-functionalized drug-loaded spinel ferrite nanoparticles

• Sadaf Mushtaq,
• Khuram Shahzad,
• Tariq Saeed,
• Anwar Ul-Hamid,
• Bilal Haider Abbasi,
• Nafees Ahmad,
• Waqas Khalid,
• Muhammad Atif,
• Zulqurnain Ali and
• Rashda Abbasi

Beilstein J. Nanotechnol. 2021, 12, 1339–1364, doi:10.3762/bjnano.12.99

• bioavailability of the encapsulated drug which allows controlled release. Additionally, the attached drug is protected from degradation, which allows an increased circulation time [6]. The targeting of specific tumor tissue is therefore achieved by an increased biodistribution process known as enhanced

Use of nanosystems to improve the anticancer effects of curcumin

• Andrea M. Araya-Sibaja,
• Norma J. Salazar-López,
• Krissia Wilhelm Romero,
• José R. Vega-Baudrit,
• J. Abraham Domínguez-Avila,
• Carlos A. Velázquez Contreras,
• Ramón E. Robles-Zepeda,
• Mirtha Navarro-Hoyos and
• Gustavo A. González-Aguilar

Beilstein J. Nanotechnol. 2021, 12, 1047–1062, doi:10.3762/bjnano.12.78

• , cell, or organelle, improving solubility, dissolution rate, and pharmacokinetics [5]. In the case of CUR, the nanosystem size directly influences its biodistribution as demonstrated by Bi et al. [41], who reported differences in the pharmacokinetic profiles when they administered CUR nanosuspension of

• the surface of CUR nanococrystals with hyaluronic acid to increase its hydrophilicity, which resulted in a better biodistribution. They reported an advantage in the release profile as a function of pH due to a lower CUR release at pH 7.4 (40%) as compared to the acidic pH (pH 5, 80%) which is